544 / 1481
Target volume reduction (4)
•
89 patients (Phase I/II clinical trial):
•
Induction chemo (cisplatin + paclitaxel +
cetuximab
±
everolimus)
•
IMRT + concurrent chemo
•
Response-adapted volume de-escalation:
•
>50% reduction after chemo
(good response): 37 pts
•
No elective neck irradiation
•
<50% reduction after chemo
(no response): 52 pts
•
Elective neck irradiation 45 Gy/bid/15 fr.
Good response
No response
Villaflor et al.
Ann Oncol
2016; 27:908-13